Pemetrexed was approved for the treatment of relapsed or chemotherapy refractory non-
small cell lung cancer patients, as it produced similar response and survival outcomes and …

Pemetrexed is a standard first-line treatment for advanced nonsquamous non–small-cell
lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) tyrosine kinase …

PURPOSE To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus
cisplatin as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA …

Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

PURPOSE: Three phase III trials have shown pemetrexed to be associated with improved
clinical outcomes among patients with adenocarcinoma and large cell histology compared …

Platinum-based chemotherapy offers a modest survival advantage over best supportive care
(BSC) in chemotherapy-naive patients with a good performance status and …

Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death
worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have …

Introduction: Recently, histology has emerged as a predictive factor for pemetrexed efficacy
in non-small cell lung cancer (NSCLC). These analyses evaluate whether the differential …

Introduction: A prespecified analysis of the large, randomized, phase III study in advanced
non-small cell lung cancer showed significant improvement in survival for nonsquamous …

Herein we describe a companion ongoing randomized phase III study in patients with
advanced nonsquamous non–small-cell lung cancer (NSCLC). Patients with chemotherapy …